Proteomic Aging Clocks Just Changed What a Phase 2a Trial Has to Prove
A Nature Biotechnology phase 2a trial ran six proteomic aging clocks simultaneously, here's what that means for biomarker strategy...
Biomarkers
Psychiatry’s Stratification Crisis: How Biomarkers Are Finally Breaking the DSM’s Grip on Trial Design
Precision psychiatry biomarkers are reshaping CNS trial stratification — here's what the shift from symptom-based DSM criteria to biotype-driven...
Harvard’s COMPASS Model Just Made Immunotherapy Trial Design More Complicated
Harvard's COMPASS AI predicts checkpoint inhibitor response across 33 cancer types with 8.5% better accuracy—but translating that into trial...
One Biomarker, Two Diseases: The p-tau Signal That Just Complicated Your Stratification Strategy
A multicenter cross-sectional study in Nature Medicine shows serum p-tau—the cornerstone of Alzheimer's blood-based diagnostics—may also detect systemic amyloidoses....